Akebia Therapeutics
AKBA
91 hedge funds and large institutions have $189M invested in Akebia Therapeutics in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 15 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 21
26% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.45M
1% more funds holding
Funds holding: 90 → 91 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
10% less capital invested
Capital invested by funds: $209M → $189M (-$20M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.13M |
| 2 |
First Manhattan
New York
|
+$8.69M |
| 3 |
PA
Perceptive Advisors
New York
|
+$4.91M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.36M |
| 5 |
VAM
Visium Asset Management
New York
|
+$3.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$4.92M |
| 2 |
Millennium Management
New York
|
-$3.65M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$2.43M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.41M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.46M |
AKBA Hedge Fund Activity: Q1 2016 in Review
91 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2016, worth a combined $189M — down 9.6% from $209M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AKBA positions and 15 closed out — a net gain of 1 holder — while 46 added to existing stakes and 21 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $9.13M. The largest seller was EAM Investors, exiting entirely with an estimated $4.92M sold.
- 91 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2016, up from 90 in Q4 2015.
- Funds reported $189M of Akebia Therapeutics stock for Q1 2016, down 9.6% quarter-over-quarter.
- 16 funds opened new Akebia Therapeutics positions in Q1 2016 and 15 closed out, a net change of +1 holder.
- The largest Akebia Therapeutics buyer in Q1 2016 was Nantahala Capital Management, an estimated $9.13M added.
- The largest Akebia Therapeutics seller in Q1 2016 was EAM Investors, an estimated $4.92M sold.
Based on aggregated 13F filings for Q1 2016.